There’s a new leader at Clinverse.
In the latest management change at the clinical trials payment software firm, a veteran Triangle executive is named chief executive officer while the firm’s founder and former CEO steps aside, the company announced Wednesday.
Denis Connaghan takes over as CEO. He most recently had served as a management consultant and as an interim executive. He is the former CEO of etrials Worldwide, which was acquired.
Tim Immel, the founder of Clinverse and its previous CEO, is now chief product officer.
Three weeks ago, the Raleigh company named Bud Owen the company’s chief financial officer and Tony Click its chief technology officer.
Owen worked most recently for Morrisville company Clinipace Worldwide, a contract research organization that markets itself as a “digital CRO.” He has been a CFO at a number of companies in software, web services, media and chemical industries participating in more than 40 merger and acquisition transactions.
Click brings to Clinverse more than 20 years of experience developing software in industries including finance, insurance, publishing, telecommunications, construction and utilities. Before joining Clinverse Click provided outsourced CTO services for early-stage startups and served as the vice president of enterprise architecture at Merkle, a database analytics company.
Clinverse provides a cloud-based financial management and payment system for the clinical trials industry. Its ClinPay platform manages financial transactions in 140 different currencies for clinical trial sites around the world.
Connaghan has more than 25 years of experience in technology, healthcare, insurance, life sciences and information technology.
“I’m thrilled to join such a fast-paced, growing company,” Connaghan said in a statement. “Clinverse’s FLS platform is an industry-first and continues to outpace the industry in terms of innovation. We are well positioned to build on this solid technology foundation, and I look forward to working with the Clinverse team to capitalize on my global and industry expertise to drive additional opportunities in the clinical trial services market.”
Immel will focus on “product excellence,” the company said.
“Of all the many responsibilities I have had at Clinverse, none has been more important to the business or more gratifying to me personallythan to design and build the exceptional products and services that we offer, products that fill an important yet unmet need in the marketplace,” said Immel. “Denis’s leadership is critical to our long-term success as we continue taking Clinverse to the heights we all envision, while delivering the highest quality service to clients.”
Clinverse was founded in 2008.
The company raised $3.8 million in venture capital in 2012.